為全球醫(yī)藥及生命科學(xué)行業(yè)提供全方位、一體化新藥研發(fā)和生產(chǎn)服務(wù)的能力和技術(shù)平臺(tái)公司--藥明康德（股票代碼：603259.SH/2359.HK）受邀出席第44屆摩根大通醫(yī)療健康大會(huì)，并在主會(huì)場(chǎng)發(fā)表演講。

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industries, has been invited to present at the 44th J.P. Morgan Healthcare Conference.

演講時(shí)間 | Presentation Session：

北京時(shí)間：2026年1月14日（周三）11:30 PM – 1月15日 (周四) 0:10 AM

Pacific Time:January 14, 2026 (Wednesday) 07:30 AM - 08:10 AM

參與方式 | Participation：

網(wǎng)絡(luò)直播（可在會(huì)議結(jié)束后30天內(nèi)回放）| Webcast (replay active for up to 30 days):

https://jpmorgan.metameetings.net/events/healthcare26/sessions/317164-wuxi-apptec/webcast?gpu_only=true&kiosk=true

演講材料將在會(huì)議結(jié)束后上傳至公司官網(wǎng):

The presentation will be available on the Company's website after the conference:

https://www.wuxiapptec.com/investors

關(guān)于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫(yī)藥及生命科學(xué)行業(yè)值得信賴的合作伙伴和重要貢獻(xiàn)者，致力于通過提供一體化、端到端的新藥研發(fā)和生產(chǎn)服務(wù)，推動(dòng)全球醫(yī)藥健康創(chuàng)新。公司在亞洲、歐洲、北美等地均設(shè)有運(yùn)營(yíng)基地，依托獨(dú)特的“CRDMO”業(yè)務(wù)模式，不斷降低研發(fā)門檻，助力客戶提升研發(fā)效率，為患者帶來(lái)突破性的治療方案。目前，公司的賦能平臺(tái)正承載著來(lái)自全球30多個(gè)國(guó)家的約6,000家合作伙伴的研發(fā)創(chuàng)新項(xiàng)目，致力于將更多新藥、好藥帶給全球病患，早日實(shí)現(xiàn)“讓天下沒有難做的藥，難治的病”的愿景。

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.